Ronapreve® is now indicated in two distinct patient populations:
Group 1: Patients admitted unwell with COVID-19 who are negative for baseline serum anti-spike (anti-S) antibodies against SARS-CoV-2.
Group 2: Patients with early hospital onset COVID-19 who are at high risk of progression to severe COVID-19 or in whom COVID-19 infection presents a material risk of destabilising a pre-existing condition or illness or compromising recovery from surgery or other hospital procedure.